Evidence map›Paper›PMID 27789118›Full record

ReviewPediatric neurology2017

Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed.

David E Mandelbaum, Suzanne M de la Monte

Abstract readCase ReportsReview
In one paragraph

Review in Pediatric neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Infant Death due to Cannabis Ingestion.Drug testing and analysis · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Cannabis use in pediatric cancer patients: what are they reading? A review of the online literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David E MandelbaumDepartments of Neurology and Pediatrics, Hasbro Children's Hospital and Rhode Island Hospital, and the Alpert Medical School of Brown University, Providence, Rhode Island.
Suzanne M de la MonteDepartments of Neuropathology and Neurosurgery, Hasbro Children's Hospital and Rhode Island Hospital, and the Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address: Suzanne_DeLaMonte_MD@Brown.edu.

Funding

Ethanol, IRS-1 Signaling and Neuronal MigrationR37AA011431 · NIAAA · RHODE ISLAND HOSPITAL · PI DE LA MONTE, SUZANNE M. · 2009 to 2018
$3.7M
EFFECTS OF ETHANOL ON INSULIN SIGNALING IN THE BRAINR01AA012908 · NIAAA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI DE LA MONTE, SUZANNE M. · 2003 to 2013
$3.0M
NIAAA NIH HHS R01 AA012908NIAAA NIH HHS R37 AA011431
6 · The paper itself

Abstract

The growing use and legalization of cannabis are leading to increased exposures across all age groups, including in adolescence. The touting of its medicinal values stems from anecdotal reports related to treatment of a broad range of illnesses including epilepsy, multiple sclerosis, muscle spasms, arthritis, obesity, cancer, Alzheimer disease, Parkinson disease, post-traumatic stress, inflammatory bowel disease, and anxiety. However, anecdotal data and the high level of interest in this treatment must not obscure objective assessments of any potential and realized short- and long-term adverse effects of cannabis, particularly with respect to age of onset and chronicity of exposure. This critical review focuses on evidence-based research designed to assess both therapeutic benefits and harmful effects of cannabis exposure and is combined with an illustration of the neuropathologic findings in a fatal case of cannabis-induced psychosis. The literature and reported case provide strong evidence that chronic cannabis abuse causes cognitive impairment and damages the brain, particularly white matter, where cannabinoid 1 receptors abound. Contrary to popular perception, there are few objective data supporting preferential use of cannabis over conventional therapy for restoration of central nervous system structure and function in disease states such as multiple sclerosis, epilepsy, or schizophrenia. Additional research is needed to determine if subsets of individuals with various neurological and psychiatric diseases derive therapeutic benefits from cannabis.

Indexed as

AnimalsBrainCannabinoidsCannabisFatal OutcomeHumansMaleMarijuana AbuseMiddle AgedPsychoses, Substance-InducedCannabinoidscannabisepilepsyhuman brainmarijuanamultiple sclerosispsychosistreatmentwhite matter

Identifiers

PMID27789118
PMCPMC9954727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.